Cadila Healthcare is planning to acquire the generic sterile injectables business of Claris Lifesciences , says report.
Shares of Claris Lifesciences were higher by 9% to Rs 307 on reports that Cadila Healthcare is planning to acquire the generic sterile injectables business of the company.
The stock has hit a high of Rs. 331 and a low of Rs. 306.
A formal announcement is expected early next month, says report.
No comments:
Post a Comment